Novo Nordisk A/S, a Danish pharmaceutical giant, recently signed a deal to acquire an experimental blood-pressure drug from KBP Biosciences in a transaction that could be worth up to $1.3 billion dollars. This acquisition adds another chapter to Novo Nordisk’s recent deals aimed at bolstering its medicinal product pipeline.
The drug in focus, ocedurenone, is currently in its late-stage testing for individuals suffering from uncontrolled hypertension and chronic kidney disease in advanced stage.
According to Novo’s development chief, Martin Holst Lange, the drug has the potential to meet a significant health need by helping patients dealing with both heart disease and chronic kidney disease.
This latest transaction is part of a series of strategic acquisitions by Novo Nordisk designed to strengthen its medicinal product portfolio.
More information on this matter can be found in this Bloomberg Law article.